Researchers think the study drug, EPI-7386, may be an effective treatment for metastatic castration-resistant prostate cancer (mCRPC) because the drug works by interfering with the function of the male hormone system that leads to the growth of prostate cancer. Enzalutamide is an androgen receptor inhibitor that works by blocking the action of male hormones (androgens) like testosterone to slow down the growth of prostate cancer. Enzalutamide is approved by the Food & Drug Administration (FDA) and is commonly used as a standard of care option for men with advanced or metastatic castration-resistant prostate cancer. Since EPI-7386 and enzalutamide have not been combined together in humans, we are doing this study to find out whether EPI-7386, in combination with a fixed dose of enzalutamide, compared to standard of care enzalutamide alone, is a safe and effective treatment for men who have mCRPC. Study will be done at Spindrift Clinic location. Read More

1) Males aged 18 years or older
2) Histologically, pathologically, or cytologically confirmed prostate adenocarcinoma
3) Presence of metastatic disease at study entry
4) Naïve to second generation anti-androgens

We are doing this study to learn more about if the combination of medications (durvalumab, tremelimumab and enfortumab vedotin)before and after bladder removal surgery will work and be safe for the treatment of muscle invasive bladder cancer. Also to better understand the disease and associated health problems. Read More

1) Participant must be 18 or older years at the time of screening
2) Histologically or cytologically documented muscle-invasive TCC of the bladder with clinical stage of T2-4aN0-N1M0
3) Medically fit for cystectomy and able to receive neoadjuvant therapy
4) Cisplatin-ineligible

The purpose of this study is to learn more about the advantages and disadvantages of two brief quitting smoking approaches that could be cost-effective in assisting individuals who suffer from serious mental illness. The first approach is brief advice combined with the use of nicotine gum and patches. The second approach uses an app on your smartphone combined with the use of nicotine gum and patches. Read More

Inclusion Criteria
(1) Current DSM-5 diagnosis of schizophrenia, schizoaffective, bipolar, or recurring major depressive disorder;
(2) Functional impairment as indicated by a score of_2 or greater on the WHODAS 8 item version
(3) Smoker as indicated by smoking  5 cigarettes per day over the past 6 months;
(4) Desire to quit smoking as indicated by self-reported serious...

Participants with or without multiple sclerosis are needed for this research study on audio-visual cognition. Participants will be asked to complete some short questionnaires and cognitive tasks over the span of approximately 2-3 hours. All testing will be completed in one session at the University at Buffalo's Division of Cognitive and Behavioral Neurosciences Laboratories. Read More

-Age range 20-65 years
-Normal Hearing and Vision
-DO NOT have the following: severe psychiatric disorder, alcohol or substance abuse or dependence, history of traumatic head injury, neurological disturbances other than multiple sclerosis.

Study to assess the effect of dapagliflozin as compared with placebo in patients with heart failure who have been stabilized during hospitalization for acute heart failure. Patients will be followed for a maximum of 2 months. Read More

1. Currently hospitalized with AHF with symptoms of AHF.
2. LVEF <40% within the past 12 months
3. Elevated NT-proBNP, >1600 pg/ml
4. > 18 years of age
5. eGFR >30

This clinical study investigates a new treatment for prostate cancer. ODM-208 (CYP11A1 inhibitor) is the oral study medication that will be taken together with oral glucocorticoid (dexamethasone) and mineralocorticoid (fludrocortisone) replacement therapy. The purpose of this study is to find a safe and effective dose of ODM-208 for the treatment of prostate cancer. The purpose of this study is also to use the results of this study to support development programs of CYP11A1 inhibitors in prostate cancer and other relevant indications. Read More

1) Males greater than or equal to 18 years. 2) Metastatic disease documented either by a positive bone scan, CT, PET/CT or MRI scan 3) Treatment with at least 1 line of taxane-based chemotherapy in castration-sensitive prostate cancer (CSPC) or in CRPC

-Adults ages 18-80
-Has a single unruptured target intracranial aneurysm (IA) located on the internal carotid artery (ICA) or its branches.

This study is being done to see if the Buffalo Concussion Physical Exam and the Tele-Brain Injury Screen can be safely used to identify brain injury and its impact on functioning in female survivors who have experienced intimate partner violence. The Buffalo Concussion Physical Exam is a non-invasive physical exam that examines neck/head area for any discomfort. This exam also tests standing balance and the ability to follow movements with eyes. The Tele-Brain Injury Screen tells us how individuals suspected of brain injury are feeling and whether the way they are feeling is interfering with their functioning. In essence, we want to understand if intimate partner violence could result in brain injury. We also want to understand the effects of brain injury on daily functioning and social functioning. Read More

18-60 years old
Proficient in English
Physical injury to head/neck/face or strangulation injury due to partner abuse within the past year
Reports of physical abuse (e.g., being thrown against an object, partner initiated fall resulting in head injury or any other reports of physical abuse resulting in whiplash injury) by an intimate partner within the past year
Phys...

This survey study examines how transgender and gender nonconforming individuals have experienced oral healthcare, how accessible such care is to them, and how they feel about receiving it. Read More

18 or greater years of age
self-identify as transgender or gender nonconforming

The University at Buffalo (UB) School of Dental Medicine is looking for volunteers to join a gum disease study. The study aims to learn more about how harmful bacteria grow in the mouth and cause periodontal (gum) disease. We are interested in Porphyromonas gingivalis (P. ginivalis), a pathogen involved in gum disease. Read More

Adults aged 25 years or older Have at least 16 natural teeth Have the bacterium Porphyromonas gingivitis in their mouth Have gum disease (which will be determined by study staff) Do not wear braces or other orthodontic equipment Have not had periodontal treatment or surgery in the past year Not currently pregnant